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Abstract
Background: Colorectal cancer (CRC) development is accompanied by changes in expression for several genes; but
the details of the underlying regulatory procesess remain unknown. Our aims were to assess the role of epigenetic
processes in tumour formation and to identify characteristic DNA methylation and miRNA alterations in the
colorectal adenoma-carcinoma sequence.
Methods: Whole genome expression profiling was performed on colonic biopsy samples (49 healthy normal, 49
colorectal adenoma (AD), 49 CRC); on laser capture microdissected (LCM) epithelial and stromal cells from 6 CRC-normal
adjacent tissue (NAT) samples pairs, and on demethylated human CRC cell lines using HGU133 Plus 2.0 microarrays
(Affymetrix). Methylation status of genes with gradually altering expression along the AD-CRC sequence was further
analysed on 10–10 macrodissected and 5–5 LCM samples from healthy colon, from adenoma and from CRC biopsy
samples using bisulfite-sequencing PCR (BS-PCR) followed by pyrosequencing. In silico miRNA prediction for the selected
genes was performed with miRWALK algorithm, miRNA expression was analysed on 3 CRC-NAT sample pairs and 3
adenoma tissue samples using the Human Panel I + II (Exiqon). SFRP1 immunohistochemistry experiments were
performed.
Results: A set of transcripts (18 genes including MAL, SFRP1, SULT1A1, PRIMA1, PTGDR) showed decreasing expression
(p < 0.01) in the biopsy samples along the adenoma-carcinoma sequence. Three of those (COL1A2, SFRP2, SOCS3) showed
hypermethylation and THBS2 showed hypomethylation both in AD and in CRC samples compared to NAT, while BCL2,
PRIMA1 and PTGDR showed hypermethylation only in the CRC group. miR-21 was found to be significantly (p < 0.01)
upregulated in adenoma and tumour samples compared to the healthy colonic tissue controls and could explain the
altered expression of genes for which DNA methylation changes do not appear to play role (e.g. BCL2, MAL, PTGS2).
Demethylation treatment could upregulate gene expression of genes that were found to be hypermethylated in human
CRC tissue samples. Decreasing protein levels of SFRP1 was also observed along the adenoma-carcinoma sequence.
Conclusion: Hypermethylation of the selected markers (MAL, PRIMA1, PTGDR and SFRP1) can result in reduced gene
expression and may contribute to the formation of colorectal cancer.
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Background
Colorectal cancer (CRC) is regarded as one of the most
frequent malignant tumours globally [1]. This heteroge-
neous disease can develop through at least three distinct
molecular pathways by which genetic and/or epigenetic
dysregulation influences gene expression and protein
levels finally leading to colorectal adenoma and carcinoma
formation [2, 3]. One of the epigenetic alterations that can
contribute to CRC formation is the abnormal DNA hyper-
methylation of promoters, resulting in reduced or absent
gene expression [4]. DNA hypermethylation occurs at
regulatory sites e.g. promoters in a tissue- and cancer
type-specific manner [5]. Besides genetic alterations, DNA
hypermethylation of tumour suppressor genes is a fre-
quently detected mechanism behind the inactivation of
these genes leading to tumour initiation [6]. Although
more and more genes are associated with various types of
cancers, our knowledge of DNA methylation markers in
CRC development remains incomplete.
Another key posttrancriptional epigenetic regulator of
gene expression, miRNA, regulates the stability and trans-
lation process of mRNAs. The expression of miRNAs has
been shown to differ in colorectal tumours compared to
healthy colon tissue specimens and on the basis of several
experimental results they play role in colorectal cancer
formation. Up- and downregulation of certain miRNAs
was identified along the adenoma-carcinoma sequence of
CRC and evidence supports the role of miRNAs in CRC
development and progression as these small non-coding
RNAs affect proliferation and invasion [7].
The identification of genes affected by epigenetic changes
can be achieved using whole genome gene expression ana-
lysis [8]. DNA methylation and miRNA expression alter-
ations can both lead to a certain degree of dowregulation of
mRNA expression and consequently of protein levels,
which can be confirmed by immunohistochemistry.
In the present study, our aims were (1) to identify DNA
methylation markers in CRC samples on the basis of
whole genome gene expression analysis and (2) to analyse
the DNA methylation levels of these candidate marker
along the colorectal adenoma-carcinoma sequence on
colorectal adenoma and cancer samples. Furthermore, (3)
our aim was to confirm the relationship between gene ex-
pression, DNA methylation status, miRNA expression and
protein levels of the analysed candidate markers.
Methods
Selection of candidate genes regulated by DNA
methylation
The selection of candidate genes was based on expression
data generated from 147 colonic biopsy specimens (from
49 normal, 49 adenoma, and 49 CRC patients), laser cap-
ture microdissected colonic epithelial cells (from 6 NAT, 6
adenomas, and 6 CRC), analysed in a previous study by
whole genome HGU133 Plus 2.0 microarrays (Affymetrix)
[8, 9]. These data files are available in the Gene Expession
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) at
GSE series accession numbers GSE4183 (8 normal, 15 ad-
enoma and 15 CRC), GSE10714 (3 normal, 5 adenoma and
7 CRC), GSE37364 (38 normal, 29 adenoma and 27 CRC))
and GSE15960 (laser microdissected colonic epithelial cells
from 6 normal, 6 adenoma and 6 CRC).Clinical data of pa-
tients involved in the analysed gene expression studies can
be found in Additional file 1: Table S1.
Although the bioinformatic analysis and the candidate
selection was based on previously performed and pub-
lished raw gene expression data of HGU133 Plus 2.0 mi-
croarrays, the aim of the present study was substantially
different from the previously published studies’. We
aimed to identify genes with gradually altering expres-
sion in adenoma and tumour samples that can be poten-
tially regulated by DNA methylation. The data sets
GSE4183 [10], GSE10714 [11], GSE 37364 [9], and
GSE15960 [8] were analysed to identify genes potentially
regulated by DNA methylation. Transcripts with grad-
ually decreasing or increasing expression along the
adenoma-carcinoma sequence were selected on the basis
of Kendall (tau coefficient) rank correlation analysis
(−0.5 ≤ tau coefficient ≤ 0.5). DNA methylation analysis
was performed for genes with CpG island(s) on the basis of
in silico prediction by the CpG Plot EMBOSS application
(http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) [12].
Expression of the selected gene set was also analysed
on gene expression data sets of human colorectal cell
lines before and after DNA demethylation treatment
with 5-Aza (GSE29060: 10 μM 5-Aza treatment for 72 h
on HT-29 cell line; GSE14526: 3 μM 5-Aza treatment
for 72 h on HCT116 and SW480 cell lines; GSE32323:
0.5 μM 5-Aza treatment for 72 h on Colo32, HCT116,
HT-29, RKO and SW480 cell lines.
Student's t -test and Benjamini-Hochberg method
were applied in order to determine significance of
gene expression and DNA methylation level compari-
sons (p < 0.05). For logFc, abs (differences of average
of intensity values) > 1 threshold was applied.
Tissue sample collection
For DNA methylation analysis, tissue specimens were
obtained from surgically removed colon tumours (mod-
erately differentiated, Dukes B-C stages; MSS) (n = 15)
and from histologically normal adjacent tissue (NAT)
(n = 15) derived from the furthest available area away
from the tumour. In addition, adenomas (n = 15) were
also analysed, containing biopsy samples (n = 10) and
fresh frozen tissue samples (n = 5), as well. Fresh fro-
zen samples were snapfrozen in liquid nitrogen dir-
ectly after surgery and were stored at −80 °C. Written
informed consent was obtained from all patients; and
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the study was approved by the local ethics committee
(Ethics Committee approval was obtained Nr.: TUKEB
2005/037 and TUKEB Nr.: 2008/69, Semmelweis University
Regional and Institutional Committee of Science and Re-
search Ethics, Budapest, Hungary). The study was performed
according to the ethical standards of the revised version of
Helsinki Declaration. Clinical data of patients involved in
the study can be found in Additional file 2: Table S2.
Laser capture microdissection, macrodissection
Frozen tissue samples were embedded in OCT compound
(Sakura Finetek, Japan). Then, 10 μm cryosections were cut
at −20 °C in a cryostat instrument and mounted on PALM
Membrane Slides 1.0 PEN (Carl Zeiss, Bernried, Germany).
After fixation with 70 % ethanol for 5 min and absolute
ethanol for 2 min, slides were stained with cresyl violet
acetate (Sigma-Aldrich, St. Louis, USA). Colonic epithelial
and stromal cells (approx. 103 cells) were collected using
the PALM Microbeam laser capture microdissection sys-
tem (PALM, Bernried, Germany). Macrodissected samples
were collected from cryosections after toluidine blue stain-
ing. Selected areas containing both stromal and epithelial
cells were harvested by scratching the tissue slide with a
single-use needle.
DNA methylation analysis
Bisulfite conversion
Bisulfite conversion was performed using the EZ DNA
Methylation Direct Kit (Zymo Research) without prior
DNA isolation. Proteinase K digestion was performed in
20 μl (according to Section I Protocol A) followed by bi-
sulfite conversion. The elution volume was 20 μl.
Bisulfite-specific PCR (BS-PCR)
In silico CpG island prediction was performed by CpG
Plot EMBOSS Application (http://www.ebi.ac.uk/Tools/
seqstats/emboss_cpgplot/). Bisulfite-specific PCR reac-
tions were performed using primers designed with Pyro-
Mark Assay Design software (SW 2.0, Qiagen, Hilden,
Germany) to be specific for non-CpG regions in order to
amplify the bisulfite converted DNA samples without
discriminating between methylated and non-methylated
sequences (Table 1). PCR primers in the opposite dir-
ection of sequencing primers were biotin labelled. Pri-
mer specificities were tested in silico by BiSearch
software (http://bisearch.enzim.hu) [13].
BS-PCR reactions were performed using AmpliTaq
Gold 360 mastermix (2x) (Life Technologies, Carlsbad,
USA), LightCycler 480 ResoLight Dye (40x) (Roche
Applied Science), primer mix (200 nM final concentra-
tion), bisulfite converted DNA samples (approx. 10 ng
bcDNA/well) in 15 μl final volume. Real-time PCR
amplification was carried out with the following thermo-
cycling conditions on the LightCycler 480 System: 95 °C
for 10 min, then 95 °C for 30 s, 60 °C with a 0.4 °C de-
crease/cycle for 30 s, 72 °C for 30 s for 10 touchdown cy-
cles, followed by the amplification at 95 °C for 30 s, 56 °C
for 30 s, and 72 °C for 30 s in 40 cycles.
Providing single-base resolution information about the
methylation status of a CpG island direct sequencing is
one of the most robust methods to analyse BS-PCR prod-
ucts. After bisulfite treatment and BS-PCR, all cytosines
are converted to thymines except for those originally meth-
ylated. Two different pyrosequencing technologies were
applied to analyse DNA methylation of BS-PCR products
i.e. the Qiagen PyroMark System and the Roche GS Junior
System utilising the 454 technology. The read length of the
different technologies differs. With the PyroMark system
sequences, up to 60 bp can be analysed, while up to 400 bp
read length could be achieved with the 454 technology.
PyroMark Q24 sequencing
Pyrosequencing was performed on a PyroMark Q24 in-
strument (Qiagen) using PyroMark Gold Q24 Reagents
(Qiagen) according to the manufacturer’s recommenda-
tions. Purification and subsequent processing of the bio-
tinylated single-stranded DNA were performed in two
consecutive runs by applying two different sequencing
primers in order to cover more CpG sites in the
Table 1 Genes analysed in the study. Genes with gradually
decreasing or increasing expression along the adenoma-
carcinoma sequence with predictable CpG islands were selected
on the basis of Kendall (tau coefficient) rank correlation analysis
(−0.5 ≤ tau coefficient≤ 0.5)
Gene symbol Gene name
ALDH1A3 aldehyde dehydrogenase 1 family, member A3
BCL2 B-cell CLL/lymphoma 2
CDX1 caudal type homeobox 1
COL1A2 collagen, type I, alpha 2
CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1
ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5
FADS1 fatty acid desaturase 1
MAL mal, T-cell differentiation protein
PRIMA1 proline rich membrane anchor 1
PTGDR prostaglandin D2 receptor (DP)
PTGS2 prostaglandin-endoperoxide synthase 2
SFRP1 secreted frizzled-related protein 1
SFRP2 secreted frizzled-related protein 2
SOCS3 suppressor of cytokine signaling 3
SULF1 sulfatase 1
SULT1A1 sulfotransferase family, cytosolic, 1A, phenol-preferring,
member 1
THBS2 thrombospondin 2
TIMP1 metallopeptidase inhibitor 1
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amplicons [14, 15]. Sequencing results were analysed
using the PyroMark Q24 software v2.0.6 (Qiagen).
GS Junior sequencing
Library preparation with ligated adaptors and emulsion-
PCR amplification were as described in “Guidelines for
Amplicon Experimental Design”. The concentrations of
BS-PCR amplicons were measured by Qubit fluorometer
with High Sensitivity dsDNA reagent (Life Technologies).
Amplicons belonging to the same sample were pooled at
an equimolar ratio and PCR products were purified with
AMPure beads (Agencourt, Beckman Coulter Genomics,
Pasadena, USA) according to the manufacturer’s standard
protocol. The Agilent Bioanalyzer was used with the High
Sensitivity DNA Chip (Agilent, Santa Clara, USA) to as-
sess sample quality. Fragment End Repair was performed
using the GS FLX Titanium Rapid Library Preparation Kit
(Rapid Library Preparation Method Manual 3.2). RL MID
Adaptor Ligation was carried out using GS FLX Titanium
Rapid Library Preparation Kit (Rapid Library Preparation
Method Manual 3.4). After ligation, purification of ampli-
con libraries was performed with AMPure beads, and as-
sessment of library quality was done using the Agilent
Bioanalyzer with High Sensitivity DNA Chip. Library
quantification was performed based on fluorometric mea-
surements with Qubit High Sensitivity dsDNA reagent.
Equimolar mixing of the libraries was performed by MIDs
identifying different samples with different MID adaptors.
Amplicon library pools were then amplified by emPCR at
a 0.5 DNA molecule per bead ratio using the Lib-L
emPCR Kit. Since amplicon lengths were short, the
emPCR procedure was performed with reduced Amp Pri-
mer quantity (emPCR Amplification Method Manual –
Lib-L, GS Junior Titanium Series, Live Amp Mix for
paired end libraries). Bead enrichment and sequencing
were performed using the GS Junior Titanium Sequencing
Kit and the method described in the Sequencing Method
Manual, GS FLX Titanium Series.
The Smith-Waterman algorithm with Gotoh’s im-
provement was used for matching the reads to template
sequences in the JAligner software package [16, 17]. As
454 technology can result in sequencing errors with ho-
mopolymer stretches e.g. in bisulfite-sequencing tem-
plates [18], gaps or insertions were frequently observed
in the sequenced reads. Reads with a minimum of 80 %
of maximum alignment score were analysed further,
after which the actual nucleotides at the potential
methylation sites were summarised.
miRNA analysis
miRNA analysis was performed on an independent
formalin-fixed, paraffin-embedded (FFPE) sample set in-
cluding CRC (n = 3), adenomas (n = 3) and NAT (n = 3)
samples. miRNA isolation was performed with the High
Pure miRNA kit (Roche) and the expression of approxi-
mate 800 miRNA were assessed on Human Panel I + II
(Exiqon) with the miRCURYTM Universal RT microRNA
PCR protocol according to the manufacturer’s instruc-
tions. Normalisation of raw Ct data was performed with
interplate calibrators followed by miR-423-5p, as a house-
keeping gene expressed at relatively constant levels in our
analysed samples. In silico miRNA prediction was per-
formed for all analysed genes using the miRWALK data-
base prediction algorithm including validated mRNA
targets [19] in order to select experimentally verified
miRNA interaction information associated with genes,
pathways, organs, diseases, cell lines, OMIM disorders,
and literature on miRNAs. Subsequently, expression of se-
lected miRNAs in normal, adenoma and cancer samples
was compared.
Immunohistochemistry
Among the analysed 18 genes, SFRP1 protein level was ana-
lysed because of the special interest of our working group.
Surgically removed colonic tissues from NAT (n = 10), AD
(n = 10), and CRC specimens (n = 10) were fixed in formalin
and embedded in paraffin and tissue microarrays (TMA)
were constructed. Four μm sections were cut, deparaffi-
nised, and rehydrated. For SFRP1 staining, antigen retrieval
was performed in TRIS EDTA buffer (pH 9.0) using a
microwave (900 W for 10 min, 340 W for 40 min). Samples
were incubated with anti–SFRP1 rabbit polyclonal antibody
(ab4193, Abcam, Cambridge, UK) diluted 1:800 for 60 min
at 37 °C. EnVision +HRP system (Labeled Polymer Anti-
Mouse, K4001, Dako) and diaminobenzidine-hydrogen per-
oxidase–chromogen substrate system (Cytomation Liquid
DAB + Substrate Chromogen System, K3468, Dako) were
used with hematoxylin counterstaining. Slides were digita-
lised using the Pannoramic Scanner p250 Flash instrument
(software version 1.11.25.0, 3DHISTECH Ltd., Budapest,
Hungary), and analysed with a digital microscope software
(Pannoramic Viewer, v. 1.11.43.0. 3DHISTECH Ltd.,
Budapest, Hungary). The semiquantitative Quick-score (Q)
method was applied for SFRP1 protein level alteration ana-
lysis. Every TMA core was scored by multiplying the per-
centage of positive cells by the given intensity value (0 for
no staining, +1 for weak, +2 for moderate, and +3 for
strong diffuse immunostaining).
Results
Gene expression analysis
Genes potentially regulated by DNA methylation were
selected on the basis of whole genome gene expression
data from previously performed microarray experiments
of 49 normal, 49 adenoma, and 49 tumour biopsy sam-
ples [9]. Based on Kendall analysis, a set of 18 tran-
scripts was selected showing continuously altering
expression (p ≤ 0.01) in the biopsy samples along the
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adenoma-carcinoma sequence (Table 1). Along colorectal
adenoma-carcinoma progression, the following genes
showed downregulation: BCL2, CDX1, ENTPD5, MAL,
PRIMA1, PTGDR, SFRP1, and SULT1A1 while the follow-
ing genes showed upregulation: ALDH1A3, COL1A2,
CYP27B1, FADS1, PTGS2, SFRP2, SOCS3, SULF1, THBS2,
and TIMP1. Gene expression alteration of BCL2, CDX1,
CYP27B1, ENTPD5, MAL, PRIMA1, PTGDR, PTGS2,
SFRP1, SOCS3 SULT1A1, and TIMP1 were found to be
significant (p < 0.05) in the adenoma versus healthy and
also in the tumour versus healthy comparison. In addition,
ALDH1A3, COL1A2, FADS1, SFRP2, SULF1, and THBS2
were found to be significantly (p < 0.01) differentially
expressed in tumour samples but not in adenomas com-
pared to healthy samples (Fig. 1, Table 2, Additional file 3:
Figure S1, Additional file 4: Table S3).
In order to investigate the cellular origin of altered gene
expression of the analysed transcript set during colorectal
cancer formation, laser capture microdissection was ap-
plied to separate epithelial and stromal cells from the co-
lonic mucosa. Significantly altered expression (p < 0.05) of
SOCS3 and PRIMA1 could be detected in epithelial cells
from normal versus adenomatous samples. Gene expres-
sion changes of BCL2, CYP27B1, COL1A2, FADS1, and
SULT1A1 were significant (p < 0.05) only in tumours com-
pared to healthy samples, while CDX1, ENTPD5, PTGDR
,and TIMP1 showed gene expression difference in both
normal vs. adenoma and normal vs. tumour comparisons
(Fig. 1, Table 2, Additional file 4: Table S3).
No significant gene expression alterations could be de-
tected in the stromal cells isolated from adenomas com-
pared to the normals, but COL1A2, FADS1, MAL,
PRIMA1, SULF1, THBS2, TIMP1 genes’ transcripts
showed significant differences (p < 0.05) in logFc values
for the tumour versus normal comparison (Fig. 1;
Additional file 4: Table S3). As stromal cells showed the
fewest gene expression alterations, we further focused
on biopsy and laser microdissected epithelial samples.
Demethylation treatment on colon adenocarcinoma cell
lines
Gene expression of the selected marker set was analysed
on data sets containing control and 5-Aza treated colon
adenocarcinoma cell lines. According to GSE29060 data,
in HT-29 adenocarcinoma cells after a demethylation
treatment 4 transcripts showed a minimally decreased ex-
pression (TIMP1, FADS1, CYP27B and SULT1A1), while
PTGS2 was found to be upregulated. HCT-116 cells
showed higher re-expression of the selected genes, as
PTGS2, THBS2 and TIMP1 also showed upregulation
(1 < logFccontrol-treated) and TIMP1 was also upregu-
lated in 5-Aza treated SW480 cells according to
GSE14526. Among the 5 CRC cell lines of GSE32323
SULT1A1 in Colo32 cells, PTGS2 in HCT-116 cells,
ALDH1A3 and SOCS3 in HT-29 cells and ALDH1A3
and TIMP1 in SW480 cells showed remarkable upregula-
tion after demethylation treatment (Fig. 2, Additional file 4:
Table S3).
DNA methylation analysis
DNA methylation was assessed in human colonic
samples using two different pyrosequencing systems.
Firstly, routinely collected biopsy samples and macro-
dissected specimens naturally containing both epithe-
lial and stromal cells were analysed. Among the 18
analysed markers (Table 1), DNA methylation was
significantly (p < 0.05) altered for six loci belonging to
four genes, in which COL1A2, SFRP2, SOCS3 showed
hypermethylation and THBS2 showed hypomethyla-
tion both in AD and in CRC samples compared to
NAT. Three additional genes, BCL2, PRIMA1, and
PTGDR showed hypermethylation only in tumour
samples (Table 3, Additional file 5: Figure S2).
Interestingly, two of the analysed regions in the THBS2
promoter conferred hypomethylation along tumour for-
mation, while the third locus examined showed signifi-
cant hypermethylation in tumours compared to NAT.
Fig. 1 Summary of genes with altered expression levels in the analysed samples. Venn diagrams display genes that exhibit significantly altered
gene expression patterns (p < 0.05) in (a) colon biopsy samples, (b) laser capture microdissected (LCM) epithelial cells, and (c) stromal cells in the
normal versus adenoma, normal versus tumour comparisons and their intersections. The majority of gene expression changes could be detected
in biopsy samples, while LCM epithelial and stromal cells show fewer altered transcript levels, primarily in normal vs. tumour comparison
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Unsupervised clustering of genes with DNA
hypermethylation
Unsupervised hierarchical clustering of DNA methyla-
tion data revealed three groups of markers in biopsy and
macrodissected sample groups. The first group of genes
(SFRP2, COL1A2, THBS2, SOCS3, CYP27B1, SULT1A1,
PRIMA1 and MAL) showed a relatively high degree of
DNA methylation already in AD and also in CRC
Table 2 Gene expression data of biopsies and laser microdissected (LCM) colon epithelial cells
Normal Adenoma CRC P-value
(N vs. Ad)
P-value
(N vs. CRC)
P-value
(Ad vs. CRC)Mean normalised intensity
values ± SD
Mean normalised intensity
values ± SD
Mean normalised intensity
values ± SD
Biopsy samples
203180_at (ALDH1A3) 6.36 ± 0.92 6.53 ± 0.86 7.29 ± 1.45 0.34 p < 0.01 p < 0.01
203685_at (BCL2) 8.90 ± 0.52 7.96 ± 1.08 6.98 ± 1.22 p < 0.01 p < 0.01 p < 0.01
206430_at (CDX1) 11.70 ± 0.28 11.17 ± 0.35 10.84 ± 0.73 p < 0.01 p < 0.01 p < 0.01
202404_s_at (COL1A2) 9.75 ± 0.78 10.25 ± 1.11 12.31 ± 1.67 0.01 p < 0.01 p < 0.01
205676_at (CYP27B1) 2.55 ± 0.10 2.88 ± 0.54 3.15 ± 0.95 p < 0.01 p < 0.01 0.09
1554094_at (ENTPD5) 6.41 ± 0.70 4.56 ± 0.79 4.15 ± 1.29 p < 0.01 p < 0.01 0.06
208963_x_at (FADS1) 4.82 ± 0.70 5.05 ± 1.14 6.36 ± 1.65 0.22 p < 0.01 p < 0.01
204777_s_at (MAL) 6.02 ± 0.62 4.86 ± 0.37 4.88 ± 0.59 p < 0.01 p < 0.01 0.86
230087_at (PRIMA1) 4.09 ± 0.97 2.20 ± 0.61 2.31 ± 0.83 p < 0.01 p < 0.01 0.47
234165_at (PTGDR) 5.84 ± 1.08 3.91 ± 1.75 2.81 ± 0.85 p < 0.01 p < 0.01 p < 0.01
204748_at (PTGS2) 4.96 ± 1.33 6.84 ± 2.50 9.88 ± 2.74 p < 0.01 p < 0.01 p < 0.01
202036_s_at (SFRP1) 4.05 ± 1.47 2.18 ± 0.62 2.51 ± 1.28 p < 0.01 p < 0.01 0.11
223121_s_at (SFRP2) 2.87 ± 0.11 2.92 ± 0.28 3.94 ± 1.74 0.29 p < 0.01 p < 0.01
227697_at (SOCS3) 6.10 ± 1.11 7.42 ± 1.65 9.81 ± 2.06 p < 0.01 p < 0.01 p < 0.01
212353_at (SULF1) 6.29 ± 1.04 7.12 ± 1.16 9.23 ± 2.15 p < 0.01 p < 0.01 p < 0.01
215299_x_at (SULT1A1) 11.94 ± 0.53 10.40 ± 0.85 10.34 ± 0.95 p < 0.01 p < 0.01 0.72
203083_at (THBS2) 2.61 ± 0.44 3.46 ± 1.54 7.67 ± 3.13 p < 0.01 p < 0.01 p < 0.01
201666_at (TIMP1) 10.29 ± 0.75 12.20 ± 0.69 12.80 ± 1.04 p < 0.01 p < 0.01 p < 0.01
LCM - colon epithelial cells
203180_at (ALDH1A3) 3.44 ± 0.83 3.35 ± 0.34 3.61 ± 0.73 0.80 0.72 0.45
203685_at (BCL2) 7.02 ± 0.64 6.94 ± 1.56 4.52 ± 2.00 0.91 p < 0.05 p < 0.05
206430_at (CDX1) 10.35 ± 0.57 9.51 ± 0.47 9.38 ± 0.53 p < 0.05 p < 0.05 0.65
202404_s_at (COL1A2) 4.27 ± 1.50 3.28 ± 0.69 7.55 ± 1.02 0.18 p < 0.01 p < 0.01
205676_at (CYP27B1) 2.75 ± 0.04 2.79 ± 0.05 3.07 ± 0.24 0.10 p < 0.01 p < 0.05
1554094_at (ENTPD5) 4.51 ± 0.68 3.80 ± 0.69 2.51 ± 0.08 0.10 p < 0.01 p < 0.01
208963_x_at (FADS1) 3.24 ± 0.21 3.18 ± 0.17 4.44 ± 1.49 0.57 0.08 0.07
204777_s_at (MAL) 2.38 ± 0.17 2.30 ± 0.00 2.31 ± 0.02 0.29 0.34 0.30
230087_at (PRIMA1) 2.63 ± 0.29 3.88 ± 1.08 2.43 ± 0.12 p < 0.05 0.14 p < 0.01
234165_at (PTGDR) 4.71 ± 0.73 3.77 ± 1.02 2.39 ± 0.09 0.10 p < 0.01 p < 0.01
204748_at (PTGS2) 2.61 ± 0.15 2.68 ± 0.24 2.51 ± 0.04 0.59 0.14 0.13
202036_s_at (SFRP1) 2.71 ± 0.35 2.76 ± 0.33 2.54 ± 0.00 0.80 0.27 0.13
223121_s_at (SFRP2) 2.35 ± 0.09 2.36 ± 0.16 2.30 ± 0.00 0.81 0.28 0.34
227697_at (SOCS3) 4.97 ± 1.91 2.82 ± 0.43 4.33 ± 1.69 p < 0.05 0.55 0.06
212353_at (SULF1) 3.08 ± 0.81 2.73 ± 0.09 3.99 ± 1.44 0.32 0.21 0.06
215299_x_at (SULT1A1) 9.35 ± 0.31 8.57 ± 1.16 7.20 ± 0.95 0.14 p < 0.01 p < 0.05
203083_at (THBS2) 2.58 ± 0.14 2.53 ± 0.00 3.54 ± 1.43 0.48 0.13 0.12
201666_at (TIMP1) 4.11 ± 1.06 6.54 ± 1.62 7.85 ± 0.57 p < 0.05 p < 0.01 0.09
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samples. The second group included most markers and
did not show remarkable difference among different
sample groups, while the third minor cluster included
only two THBS2 loci with high methylation levels across
all samples (Fig. 3a). Unsupervised hierarchical cluster-
ing of LCM epithelial cells revealed similar relationships
to those in biopsy and macrodissected samples above.
Certain genes showed relatively high DNA methylation
levels in both biopsies and epithelial cells in adenoma
and cancer cases, as PRIMA1, SFRP1, SFRP2, MAL,
SOCS3, CYP27B1, COL1A2 and SULT1A1. THBS2
showed high methylation levels across all samples. The
second major marker group included most genes and
did not show remarkable difference between the differ-
ent sample groups (Fig. 3b).
miRNA analysis
We used the miRWALK database to predict miRNAs
that could target genes of our selected set. Multiple miR-
NAs could be predicted using the miRWALK ’Validated
Target’ in silico searching application. Certain groups of
miRNAs were predicted to target more genes analysed
in our present study; miR-21 (predicted for BCL2, MAL,
PTGS2, SFRP1, SOCS3) expression was found to be re-
markably upregulated in CRC compared to NAT (Fig. 4).
Furthermore, miR-21* (predicted for BCL2, MAL,
SFRP1, SOCS3, PTGS2), miR-181c (predicted for
ALDH1A3, BCL2, MAL), and let-7i* (predicted for
BCL2, CYP27B1, and SOCS3) were also found to be up-
regulated in AD and CRC samples (Fig. 4).
Immunohistochemistry
Colonic FFPE tissue samples were immunostained for
SFRP1. In NAT epithelium, moderate diffuse cytoplasmic
staining (+2) could be detected (Fig. 5a, white arrows) in
contrast to adjacent myofibroblasts (we identified they by
their localisation and morphology) with strong diffuse im-
munostaining (+3) (Fig. 5a, red arrows). In tubular AD
samples, weak diffuse cytoplasmic protein expression (+1)
was accompanied by strong and spotted immunostaining
(+2/+3) (Fig. 5b). The majority of CRC cases (9 out of 10
cases) showed weak (+1) or no (0) SFRP1 immunostaining
(Fig. 5c). According to Q-score values used for semi-
quantitative immunohistochemistry analysis, the over-
all SFRP1 protein expression decreased along the
colorectal adenoma-carcinoma sequence (Fig. 5).
Discussion
The goal of this study was to identify DNA methylation
and miRNA markers associated with the sequence of
adenoma-carcinoma formation leading to CRC. The can-
didate markers were selected based on whole genome gene
expression array data, DNA methylation analysis, and in
silico prediction and validation of miRNA expression.
The study identified set of 18 transcripts showing con-
tinuous gene expression alterations that correlated
with CRC progression. Microarray experiments revealed 12
genes (BCL2, CDX1, CYP27B1, ENTPD5, MAL, PRIMA1,
PTGDR, PTGS2, SFRP1, SOCS3, SULT1A1, and TIMP1)
with significantly different transcriptional activities in AD
compared to NAT controls, while 6 genes (ALDH1A3,
Fig. 2 Heat map of gene expression data of the selected marker set in 5-aza-2’-deoxycytidine-treated human colon adenocarcinoma cells
(GSE29060; GSE14526; GSE32323). Intensity values on the colour scale were as follows: red – high intensity, black – intermediate intensity,
green – low intensity. Demethylation treatment resulted in varying degrees of upregulation of certain transcripts
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Table 3 DNA methylation data of biopsies, macrodissected samples and laser microdissected (LCM) colon epithelial cells
Normal Adenoma CRC P-value
(N vs. Ad)
P-value
(N vs. CRC)
P-value
(Ad vs. CRC)Mean DNA methylation
% ± SD
Mean DNA methylation
% ± SD
Mean DNA methylation
% ± SD
Biopsy samples
ALDH1A3_assay 1 4.33 ± 2.23 3.59 ± 1.92 5.74 ± 6.26 0.31 0.36 0.21
BCL2_assay 1 3.22 ± 1.12 3.50 ± 2.21 9.74 ± 13.41 0.63 p < 0.05 0.09
BCL2_assay 2 0.91 ± 0.72 0.42 ± 0.41 0.73 ± 0.59 p < 0.05 0.44 0.11
CDX1_assay 1 21.96 ± 9.38 19.41 ± 8.76 16.01 ± 9.83 0.42 0.08 0.32
COL1A2 assay 2 22.67 ± 5.62 37.37 ± 14.36 39.52 ± 18.02 p < 0.01 p < 0.01 0.72
COL1A2_assay 1 8.65 ± 3.63 9.77 ± 6.13 15.31 ± 12.57 0.51 p < 0.05 0.14
CYP27B1_assay 1 10.71 ± 3.14 8.53 ± 4.19 11.37 ± 6.76 0.09 0.71 0.18
CYP27B1_assay 2 4.03 ± 4.16 2.71 ± 1.69 6.45 ± 10.56 0.26 0.36 0.19
CYP27B1_assay 4 45.12 ± 2.66 44.50 ± 2.08 46.70 ± 8.04 0.46 0.42 0.31
ENTPD5_assay 1 2.17 ± 0.62 1.78 ± 0.91 2.93 ± 3.32 0.15 0.35 0.20
FADS1_assay 1 0.75 ± 0.44 0.46 ± 0.23 6.98 ± 10.82 p < 0.05 p < 0.05 p < 0.05
MAL_assay 1 16.46 ± 16.12 38.87 ± 26.52 50.42 ± 26.99 p < 0.01 p < 0.01 0.25
PRIMA1_assay 1 7.25 ± 3.15 9.88 ± 10.60 28.91 ± 22.65 0.30 p < 0.01 p < 0.01
PRIMA1_assay 2 3.99 ± 1.32 6.49 ± 5.60 22.29 ± 20.14 0.06 p < 0.01 p < 0.01
PRIMA1_assay 3 37.96 ± 13.57 48.13 ± 20.69 56.43 ± 21.17 0.11 p < 0.01 0.30
PRIMA1_assay 4 8.30 ± 7.95 17.78 ± 13.26 26.82 ± 25.00 p < 0.05 p < 0.01 0.23
PTGDR assay 1 5.79 ± 1.84 4.09 ± 1.85 11.12 ± 9.36 p < 0.05 p < 0.05 p < 0.01
PTGDR assay 2 11.71 ± 3.51 8.01 ± 4.50 15.58 ± 6.48 p < 0.05 p < 0.05 p < 0.01
PTGDR_assay 3 6.47 ± 9.27 3.61 ± 4.63 10.47 ± 9.51 0.28 0.22 p < 0.05
PTGS2_assay 1 8.82 ± 3.47 12.15 ± 15.01 10.80 ± 13.16 0.34 0.52 0.80
PTGS2_assay 2 4.33 ± 9.01 5.83 ± 10.49 5.64 ± 8.48 0.65 0.67 0.96
SFRP1_assay 1 39.60 ± 18.46 60.82 ± 20.41 54.49 ± 18.47 p < 0.01 p < 0.05 0.38
SFRP2_assay 1 14.84 ± 4.38 38.52 ± 20.06 44.44 ± 20.05 p < 0.01 p < 0.01 0.43
SFRP2_assay 2 20.14 ± 4.48 39.33 ± 17.77 48.04 ± 16.20 p < 0.01 p < 0.01 0.17
SOCS3_assay 1 4.96 ± 1.52 7.57 ± 6.18 12.16 ± 12.01 0.08 p < 0.05 0.20
SOCS3_assay 2 18.24 ± 7.68 49.27 ± 20.49 49.43 ± 18.81 p < 0.01 p < 0.01 0.98
SOCS3_assay 3 8.82 ± 16.20 21.75 ± 21.72 25.79 ± 22.22 0.05 p < 0.05 0.62
SULF1_assay 1 5.32 ± 2.16 6.80 ± 11.30 9.60 ± 8.91 0.57 p < 0.05 0.46
SULF1_assay 2 4.60 ± 4.02 7.98 ± 10.78 11.28 ± 14.82 0.21 0.06 0.49
SULT1A1_assay 1 5.51 ± 4.35 3.25 ± 1.99 7.58 ± 9.46 0.07 0.39 0.09
SULT1A1_assay 2 42.68 ± 5.54 44.86 ± 9.49 48.80 ± 10.07 0.40 p < 0.05 0.28
SULT1A1_assay 3 3.11 ± 2.94 2.14 ± 1.66 6.34 ± 6.55 0.26 0.06 p < 0.05
THBS2_assay 1 18.17 ± 5.03 26.47 ± 13.79 28.36 ± 16.92 p < 0.05 p < 0.05 0.74
THBS2_assay 2 91.32 ± 2.37 85.64 ± 6.49 83.73 ± 6.83 p < 0.01 p < 0.01 0.44
THBS2_assay 3 89.68 ± 1.80 87.51 ± 3.55 83.02 ± 6.69 p < 0.05 p < 0.01 p < 0.05
THBS2_assay 4 22.32 ± 10.74 27.97 ± 13.58 25.47 ± 15.20 0.18 0.48 0.64
TIMP1_assay 1 19.54 ± 14.39 16.65 ± 14.45 13.96 ± 10.07 0.56 0.21 0.56
LCM – colon epithelial cells
ALDH1A3_assay 1 8.30 ± 3.96 4.02 ± 2.56 3.60 ± 3.49 0.08 0.08 0.83
BCL2_assay 1 3.14 ± 1.18 3.30 ± 1.19 4.26 ± 2.58 0.84 0.40 0.47
BCL2_assay 2 4.53 ± 7.59 0.32 ± 0.35 0.33 ± 0.47 0.24 0.30 0.99
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COL1A2, FADS1, SFRP1, SULF1, and THBS2) showed
unique gene expression alterations only in CRC samples.
More specifically, looking at cellular components of the
abovementioned stages of CRC formation, the results
showed that epithelial cells in AD express decreased
amounts of SOCS3 and PRIMA1, whereas those in CRC ex-
press less BCL2, CYP27B1, COL1A2, FADS1, and
SULT1A1.
Demethylation treatment of colon adenocarcinoma
cell lines led to varying degrees of upregulation of cer-
tain transcripts. In HT-29 cell line ALDH1A3 and
SOCS3 was found to be upregulated by 0.5 μM 5-Aza.
Interestingly, in HCT-116 cells PTGS2; and in SW480
cell line TIMP1 showed higher expression after 0.5 and
3 μM 5-Aza treatments, as well.
From the resulting marker set, COL1A2, SFRP2, and
SOCS3 were hypermethylated and THBS2 was hypo-
methylated in both AD and CRC samples compared to
NAT. Based on the literature, hypermethylation of
COL1A2 was confirmed in head and neck cancer [20],
melanoma [21], and bladder cancer [22]. This is suggest-
ive that COL1A2 may contribute to the formation of
various cancers by modulating cell proliferation and migra-
tion. In the gastrointestinal tract, expression of COL1A2
Table 3 DNA methylation data of biopsies, macrodissected samples and laser microdissected (LCM) colon epithelial cells (Continued)
CDX1_assay 1 11.26 ± 19.16 1.64 ± 1.16 2.43 ± 2.43 0.29 0.40 0.54
COL1A2 assay 2 19.18 ± 6.95 61.72 ± 18.25 53.46 ± 18.52 p < 0.01 p < 0.01 0.50
COL1A2_assay 1 6.46 ± 3.34 14.06 ± 6.37 22.84 ± 7.00 p < 0.05 p < 0.01 0.07
CYP27B1_assay 1 10.20 ± 12.19 3.28 ± 0.94 7.88 ± 7.06 0.24 0.75 0.19
CYP27B1_assay 2 7.14 ± 8.88 0.50 ± 0.31 6.38 ± 8.64 0.13 0.90 0.17
CYP27B1_assay 4 43.56 ± 2.13 44.90 ± 3.89 45.90 ± 5.26 0.52 0.38 0.74
ENTPD5_assay 1 1.68 ± 0.56 1.74 ± 0.11 1.88 ± 0.60 0.80 0.62 0.62
FADS1_assay 1 12.76 ± 17.16 4.70 ± 7.95 2.94 ± 5.80 0.37 0.26 0.70
MAL_assay 1 11.76 ± 10.80 61.16 ± 40.61 84.68 ± 11.92 p < 0.05 p < 0.01 0.25
PRIMA1_assay 1 4.00 ± 0.85 32.56 ± 31.71 26.42 ± 33.03 0.08 0.17 0.77
PRIMA1_assay 2 2.34 ± 1.13 29.82 ± 22.74 29.45 ± 35.82 p < 0.05 0.13 0.99
PRIMA1_assay 3 21.70 ± 25.92 73.64 ± 28.56 93.55 ± 3.06 p < 0.05 p < 0.01 0.21
PRIMA1_assay 4 0.62 ± 0.73 43.61 ± 29.53 59.91 ± 31.31 p < 0.05 p < 0.01 0.42
PTGDR assay 1 2.95 ± 0.80 3.16 ± 2.52 28.94 ± 10.72 0.87 p < 0.01 p < 0.01
PTGDR assay 2 6.40 ± 3.82 3.56 ± 1.26 23.81 ± 10.40 0.15 p < 0.01 p < 0.01
PTGDR_assay 3 1.63 ± 3.23 1.14 ± 1.45 25.72 ± 20.81 0.77 p < 0.05 p < 0.05
PTGS2_assay 1 5.80 ± 6.58 2.33 ± 0.33 3.05 ± 1.00 0.27 0.44 0.17
PTGS2_assay 2 9.66 ± 8.80 0.83 ± 0.80 18.19 ± 36.43 0.06 0.62 0.32
SFRP1_assay 1 19.03 ± 25.20 78.72 ± 23.36 91.08 ± 5.91 p < 0.01 p < 0.01 0.28
SFRP2_assay 1 12.53 ± 5.01 55.95 ± 31.32 90.78 ± 1.56 p < 0.05 p < 0.01 0.06
SFRP2_assay 2 16.34 ± 9.82 68.90 ± 27.80 85.16 ± 2.56 p < 0.01 p < 0.01 0.29
SOCS3_assay 1 3.86 ± 0.84 6.57 ± 5.39 25.07 ± 14.20 0.30 p < 0.05 p < 0.05
SOCS3_assay 2 14.28 ± 8.30 68.61 ± 35.98 90.36 ± 8.66 p < 0.05 p < 0.01 0.28
SOCS3_assay 3 2.59 ± 2.72 55.24 ± 43.52 85.04 ± 12.02 p < 0.05 p < 0.01 0.23
SULF1_assay 1 4.62 ± 4.06 7.52 ± 8.25 16.12 ± 17.25 0.50 0.18 0.34
SULF1_assay 2 4.75 ± 4.58 8.35 ± 12.00 8.46 ± 4.78 0.59 0.31 0.99
SULT1A1_assay 1 2.54 ± 1.05 4.63 ± 3.81 4.02 ± 2.15 0.27 0.20 0.76
SULT1A1_assay 2 45.35 ± 7.51 38.07 ± 4.36 56.53 ± 26.33 0.10 0.39 0.16
SULT1A1_assay 3 13.90 ± 16.07 7.69 ± 8.11 7.87 ± 12.23 0.47 0.57 0.98
THBS2_assay 1 13.64 ± 6.67 45.55 ± 25.89 49.61 ± 8.64 p < 0.05 p < 0.01 0.75
THBS2_assay 2 90.83 ± 2.02 84.92 ± 8.28 83.33 ± 10.87 0.16 0.17 0.80
THBS2_assay 3 90.16 ± 2.37 87.54 ± 3.22 78.65 ± 8.85 0.18 p < 0.05 0.07
THBS2_assay 4 24.84 ± 18.37 42.88 ± 8.47 42.48 ± 18.50 0.11 0.33 0.97
TIMP1_assay 1 32.62 ± 21.75 15.35 ± 20.90 5.35 ± 2.27 0.24 p < 0.05 0.32
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Fig. 3 Heatmap representing level of DNA methylation in a) NAT, AD, and CRC biopsies and macrodissected samples and in b) NAT, AD and CRC
LCM epithelial cells. Intensity values on the colour scale were as follows: red - high intensity, black - intermediate intensity, green - low intensity.
Samples are shown in columns, selected genes are in rows. Similar DNA methylation pattern could be found in both sample types, as PRIMA1,
SFRP1, SFRP2, MAL, SOCS3, CYP27B1, COL1A2 and SULT1A1 showed relatively high DNA methylation levels in colon biopsies and LCM epithelial cells
Fig. 4 Normalised Ct values of selected miRNAs (hsa-miR-21, hsa-miR-21*, hsa-miR-181c, hsa-let-7i*) targeting the selected marker set. Raw Ct data
were substracted from the maximal qPCR cycle number (45) and data were normalised with interplate calibrators and also with miR-423-5p Ct
values. Red dots represent individual miRNA normalised Ct values, box plots represent median and standard deviation of the data
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may be associated with endothelial-to-mesenchymal transi-
tion [23]. Collagen production of carcinoma cells decreases
during oncogenic transformation [24]; and, hypermethyla-
tion of COL1A2 was confirmed in several CRC cell lines
(HCT 116, SW480, and SW620) as well as in primary CRC
tissues [25]. SFRP2 is a member of the well-known inhibi-
tors of Wnt pathway, abnormal activation of which (e.g. via
APC mutation or beta-catenin translocation) is a frequent
and early event in the genesis of CRC [26]. It has already
been shown to be hypermethylated in colorectal cancer cell
lines (e.g. HCT116) as well as primary CRC [27, 28]. Fur-
thermore, it has recently been recognised as a promising
and sensitive marker of stool-based screening of CRC [26].
SOCS3 is a negative regulator of the JAK-STAT3 pathway;
therefore, it may effect cell proliferation and cell cycle [29].
Mutational analysis of the gene revealed no marked associ-
ation between SOCS3 promoter region polymorphisms and
the risk of developing metastatic colorectal cancer [30]. Epi-
genetic inactivation of SOCS3 was reported in human ma-
lignant melanomas and glioblastoma multiforme [31, 32].
Reduced gene expression of SOCS3 was found in the colitis
ulcerosa (UC) to CRC progression from low-grade dyspla-
sia to CRC. Related to this, DNA methylation of SOCS3
could also be detected in colonic biopsies of UC-CRC pa-
tients but not from healthy controls or from inactive UC
patients [33, 34]. THBS2 hypermethylation might be re-
sponsible for altered expression of thrombospondin-2 pro-
tein in ovarian cancer and endometrial adenocarcinomas
[35]. Thrombospondin-2 is an antiangiogenetic factor in
CRC and its expression was associated with angiogenesis
and metastasis formation inhibition in CRC [36].
The set of BCL2, PRIMA1, and PTGDR showed hyper-
methylation only in CRC. BCL2 (B-cell CLL/lymphoma
2) is an apoptotic inhibitor. Its hypermethylation was
documented in breast cancer [37] and bladder cancer
[38]. Bcl-2 protein plays a role in CRC formation [39]
and has a reduced expression in CRCs with microsatel-
lite instability [40]. DNA hypermethylation of BCL2 was
detected in CRC cases; however, there was no relation-
ship between gene expression and methylation of spe-
cific CpG sites [41]. PRIMA1 encodes a membrane
protein anchoring acetylcholinesterase to cell membranes
Fig. 5 Continuously decreasing SFRP1 protein expression could be observed along colorectal adenoma-carcinoma development in epithelial/CRC
compartment of NAT (a), AD (b), and CRC (c) samples. SFRP1 protein expression of healthy epithelial cells (a, white arrows) was compared to that
in endogenous myofibroblasts (a, red arrows) with strong (+3) immunopositivity (digital microscopy images, 90x magnification, scale bar: 20 μm).
Semiquantitative immunohistochemistry results (Q-score values) of NAT, AD, and CRC specimens are summarised as bar charts with whiskers
representing standard deviation (d)
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[42]. Its promoter hypermethylation was detected in major
depressive disorder with a concomitant decrease in gene
expression [43]. It has not yet been associated with CRC
development. Decreased mRNA expression levels of
PTGDR genes in colorectal AD and CRC caused by DNA
methylation were previously described [8].
In summaryMAL, PRIMA1, PTGDR and SFRP1 showed
a downregulation of gene expression and in parallel in-
creasing DNA methylation level that correlated with CRC
development. Meanwhile, BCL2, CDX1, ENTPD5 and
SULT1A1 dowregulation was not accompanied with sig-
nificant DNA methylation changes; thus, other regulatory
processes should be further investigated to understand
these changes in gene expression.
After DNA methylation analysis of candidate genes
with altered gene expression, the potential influence of
DNA methylation on the protein level was also investi-
gated. Significantly decreasing protein levels of SFRP1
could be observed along the adenoma-carcinoma se-
quence. This result is in accordance with the literature,
as epigenetic regulation of SFRP1 can lead to decreased
protein levels [44, 45].
On a limited sample set miRNAs with upregulation
along the AD-CRC sequence were also identified. miR-
21 was found to be remarkably upregulated in AD and
CRC samples compared to NAT controls. On the basis
of in silico prediction miR-21 can target genes showing
no remarkable alteration in their promoter methylation
(e.g. BCL2, MAL, PTGS2) during CRC development,
that might influence their gene expression levels. miR-
21 is known to play role in tumour formation and was
also found to be upregulated in CRC tissues along
tumour formation [46, 47]. The expression level of miR-
21 is elevated both in colorectal adenomas and cancers,
and the degree of upregulation correlates with more ad-
vanced stages of CRC [7]. This small non-coding RNA
could have a fundamental role in the progression of
CRC, as elevated level of miR-21 was found to be pre-
dictive of poor survival [48], that may increase prolifera-
tion, migration and invasion. In CRC cell lines with the
EMT phenotype the expression of miR-21 oncomiR is
regulated by AP-1 and ETS transciption factors and also
by epigenetic factors. Activating histone modifications
(H3K3me3, H3K914ac, H3K27ac), but no inactivating
were detected on miR-21 promoter region [49]. These
epigenetic mechanisms can affect the binding affinity of
transcription factors to the miR-21 promoter regulating
its expression level. Upregulated miR-181 in CRC cases
might also influence gene expression level of the Bcl-2
family members [50].
Conclusion
In summary, we identified 18 transcripts with changes in
gene expression that correlate with CRC development. On
the basis of genome-wide gene expression-based screening
we could identify genes potentially downregulated by pro-
moter hypermethylation. Silencing of the markers identi-
fied in our study by hypermethylation or miRNA
upregulation can result in reduced gene expression lead-
ing to decreased protein levels contributing to CRC
formation.
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